<DOC>
	<DOCNO>NCT02645734</DOCNO>
	<brief_summary>In double clinical trial 132 patient history DME ( Diabetic Macular Edema ) receive intravitreous bevacizumab dose 1.25mg ( 44 patient ) , ziv-aflibercept dose 1.25 mg ( 44 patient ) , ziv-aflibercept dose 2.5 mg ( 44 patient ) . The study drug administer often every 4 week 3 months.monitoring best-corrected visual acuity , CST ( Central Subfield Thickness ) OCT ( Optical coherence tomography ) do base line ,4 week , 8weeks injection .</brief_summary>
	<brief_title>The Effect Bevacizumab Ziv-aflibercept Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>The patient least 18 year old type 1 2 diabetes presented Central DME involvement ( defined retinal thickening involve 1mm central sub field thickness ( CCT ) Have least BCVA ( best correct visual acuity ) 20/50 20/320 Snellen equivalent Have receive antiVEGF ( anti vascular endothelial growth factor ) laser treatment within previous 3 month Uncontrolled glaucoma/uncontrolled diabet , high risk PRP ( panretinal photocoagulation ) , one eye Prior treatment intravitreal peribulbar injection laser therapy last 3 month Substantial cataract , history uveitis Macular edema due cause DME VMT ( Vitreomacular traction ) ERM ( epiretinal membrane )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>